NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 74 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q1 2016. The put-call ratio across all filers is 0.28 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $13,000 | -18.8% | 30,587 | -4.7% | 0.00% | – |
Q2 2017 | $16,000 | -20.0% | 32,087 | -5.9% | 0.00% | – |
Q1 2017 | $20,000 | -9.1% | 34,087 | 0.0% | 0.00% | – |
Q4 2016 | $22,000 | -29.0% | 34,087 | 0.0% | 0.00% | – |
Q3 2016 | $31,000 | +72.2% | 34,087 | 0.0% | 0.00% | – |
Q2 2016 | $18,000 | -45.5% | 34,087 | -2.1% | 0.00% | – |
Q1 2016 | $33,000 | -28.3% | 34,802 | 0.0% | 0.00% | – |
Q4 2015 | $46,000 | -43.9% | 34,802 | -2.8% | 0.00% | -100.0% |
Q3 2015 | $82,000 | +34.4% | 35,802 | -5.3% | 0.00% | 0.0% |
Q2 2015 | $61,000 | +1.7% | 37,802 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $60,000 | -15.5% | 37,802 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $71,000 | +34.0% | 37,802 | -5.0% | 0.00% | 0.0% |
Q3 2014 | $53,000 | -14.5% | 39,802 | -4.8% | 0.00% | 0.0% |
Q2 2014 | $62,000 | -16.2% | 41,814 | +4.3% | 0.00% | 0.0% |
Q1 2014 | $74,000 | -7.5% | 40,099 | +3.9% | 0.00% | 0.0% |
Q4 2013 | $80,000 | -13.0% | 38,599 | +10.6% | 0.00% | 0.0% |
Q3 2013 | $92,000 | +4.5% | 34,884 | +6.1% | 0.00% | -50.0% |
Q2 2013 | $88,000 | – | 32,884 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Platinum Management (NY) LLC | 10,375,329 | $13,549,000 | 19.76% |
Catalyst Capital Advisors LLC | 790,000 | $1,635,000 | 0.53% |
DSC Advisors, L.P. | 500,000 | $1,035,000 | 0.50% |
STONERIDGE INVESTMENT PARTNERS LLC | 142,528 | $295,000 | 0.06% |
Hudock, Inc. | 30,500 | $63,000 | 0.05% |
BRR OpCo, LLC | 52,700 | $109,000 | 0.05% |
TFS CAPITAL LLC | 418,074 | $865,000 | 0.04% |
LifePlan Financial Group, Inc | 28,810 | $60,000 | 0.04% |
NOMURA HOLDINGS INC | 3,831,177 | $7,947,000 | 0.04% |
BOLTON LP | 77,400 | $160,000 | 0.03% |